Theravance Biopharma Inc (NASDAQ:TBPH) – Leerink Swann upped their FY2018 EPS estimates for Theravance Biopharma in a report issued on Wednesday, November 7th. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will post earnings of ($4.48) per share for the year, up from their previous forecast of ($4.53). Leerink Swann currently has a “Buy” rating and a $38.00 price target on the stock. Leerink Swann also issued estimates for Theravance Biopharma’s Q4 2018 earnings at ($1.41) EPS, FY2019 earnings at ($4.77) EPS, FY2020 earnings at ($3.51) EPS, FY2021 earnings at ($4.38) EPS and FY2022 earnings at ($3.04) EPS.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.18) by $0.08. The business had revenue of $12.84 million for the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 355.48%.

A number of other analysts also recently weighed in on the stock. BidaskClub downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, July 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, August 1st. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $55.00 target price on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Finally, ValuEngine raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $47.00.

Shares of Theravance Biopharma stock opened at $25.81 on Friday. The company has a current ratio of 4.14, a quick ratio of 3.95 and a debt-to-equity ratio of 6.52. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -4.74 and a beta of 2.09. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $35.48.

In other news, SVP Philip D. Worboys sold 6,393 shares of the company’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $28.50, for a total value of $182,200.50. Following the sale, the senior vice president now directly owns 166,753 shares of the company’s stock, valued at approximately $4,752,460.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Renee D. Gala sold 43,743 shares of the company’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $26.79, for a total transaction of $1,171,874.97. The disclosure for this sale can be found here. Insiders sold a total of 57,255 shares of company stock worth $1,551,343 over the last ninety days. Insiders own 6.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its position in shares of Theravance Biopharma by 4.6% in the 2nd quarter. Rhumbline Advisers now owns 39,781 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 1,757 shares during the period. UBS Group AG boosted its stake in Theravance Biopharma by 88.4% in the 1st quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 2,117 shares in the last quarter. Royal Bank of Canada boosted its stake in Theravance Biopharma by 22.3% in the 1st quarter. Royal Bank of Canada now owns 16,664 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 3,042 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Theravance Biopharma by 12.2% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 28,578 shares of the biopharmaceutical company’s stock worth $648,000 after purchasing an additional 3,100 shares in the last quarter. Finally, Alps Advisors Inc. boosted its stake in Theravance Biopharma by 9.7% in the 2nd quarter. Alps Advisors Inc. now owns 79,607 shares of the biopharmaceutical company’s stock worth $1,805,000 after purchasing an additional 7,043 shares in the last quarter. 84.74% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Read More: Price to Earnings Ratio (PE), For Valuing Stocks

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.